Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients

Clinical Immunology

Volumn 135, Issue 1, 2010, Pages 33-42

  Berthelot, Laureline ^a   Miqueu, Patrick ^a,b   Pettré, Ségolène ^a   Guillet, Marina ^b   Moynard, Julien ^a   Wiertlewski, Sandrine ^c   Lefrère, Fabienne ^c   Brouard, Sophie ^a   Soulillou, Jean Paul ^a,d   Laplaud, David Axel ^a,c  

^a INSERM   (France)

^b TcLand Expression   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

CDR3 region; ; Glatiramer acetate; ; Multiple sclerosis; ; Repertoire; T cell receptor;

Indexed keywords

AUTOANTIGEN; BRAIN DERIVED NEUROTROPHIC FACTOR; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLATIRAMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; NERVE GROWTH FACTOR; NEUROTROPHIN 3; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TREATMENT FAILURE; ELECTROPHORESIS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LONG TERM CARE; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELAPSE; REMISSION; SHORT COURSE THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMPLEMENTARITY DETERMINING REGIONS; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVE GROWTH FACTORS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 77949267602     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.12.006     Document Type: Article

References (46)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
2. Farina C., Weber M.S., Meinl E., Wekerle H., and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet. Neurol. 4 (2005) 567-575
3. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
4. Aharoni R., Teitelbaum D., Leitner O., Meshorer A., Sela M., and Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11472-11477
5. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., and Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105 (2000) 967-976
6. Wiesemann E., Klatt J., Sonmez D., Blasczyk R., Heidenreich F., and Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J. Neuroimmunol. 119 (2001) 137-144
7. Kantengwa S., Weber M.S., Juillard C., Benkhoucha M., Fellay B., Zamvil S.S., Gougeon M.L., Chofflon M., and Lalive P.H. Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J. Neuroimmunol. 185 (2007) 123-129
8. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., and Kapsenberg M.L. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170 (2003) 4483-4488
9. Kim H.J., Ifergan I., Antel J.P., Seguin R., Duddy M., Lapierre Y., Jalili F., and Bar-Or A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol. 172 (2004) 7144-7153
10. Sanna A., Fois M.L., Arru G., Huang Y.M., Link H., Pugliatti M., Rosati G., and Sotgiu S. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 143 (2006) 357-362
11. Weber M.S., Prod'homme T., Youssef S., Dunn S.E., Rundle C.D., Lee L., Patarroyo J.C., Stuve O., Sobel R.A., Steinman L., and Zamvil S.S. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13 (2007) 935-943
12. Aharoni R., Teitelbaum D., Arnon R., and Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 634-639
13. Fridkis-Hareli M., Stern J.N., Fugger L., and Strominger J.L. Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses. Hum. Immunol. 62 (2001) 753-763
14. Putheti P., Soderstrom M., Link H., and Huang Y.M. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J. Neuroimmunol. 144 (2003) 125-131
15. Hong J., Li N., Zhang X., Zheng B., and Zhang J.Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6449-6454
16. Jee Y., Piao W.H., Liu R., Bai X.F., Rhodes S., Rodebaugh R., Campagnolo D.I., Shi F.D., and Vollmer T.L. CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin. Immunol. 125 (2007) 34-42
17. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 (2002) 2381-2391
18. Chen M., Valenzuela R.M., and Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol. Sci. 215 (2003) 37-44
19. Biegler B.W., Yan S.X., Ortega S.B., Tennakoon D.K., Racke M.K., and Karandikar N.J. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J. Neuroimmunol. 180 (2006) 159-171
20. Guillet M., Brouard S., Gagne K., Sebille F., Cuturi M.C., Delsuc M.A., and Soulillou J.P. Different qualitative and quantitative regulation of V beta TCR transcripts during early acute allograft rejection and tolerance induction. J. Immunol. 168 (2002) 5088-5095
21. Laplaud D.A., Ruiz C., Wiertlewski S., Brouard S., Berthelot L., Guillet M., Melchior B., Degauque N., Edan G., Brachet P., Damier P., and Soulillou J.P. Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain 127 (2004) 981-995
22. Laplaud D.A., Berthelot L., Miqueu P., Bourcier K., Moynard J., Oudinet Y., Guillet M., Ruiz C., Oden N., Brouard S., Guttmann C.R., Weiner H.L., Khoury S.J., and Soulillou J.P. Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. J. Neuroimmunol. 177 (2006) 151-160
23. Rio J., Nos C., Tintore M., Tellez N., Galan I., Pelayo R., Comabella M., and Montalban X. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59 (2006) 344-352
24. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
25. Brouard S., Vanhove B., Gagne K., Neumann A., Douillard P., Moreau A., Cuturi C., and Soulillou J.P. T cell repertoire alterations of vascularized xenografts. J. Immunol. 162 (1999) 3367-3377
26. Douillard P., Pannetier C., Josien R., Menoret S., Kourilsky P., Soulillou J.P., and Cuturi M.C. Donor-specific blood transfusion-induced tolerance in adult rats with a dominant TCR-Vbeta rearrangement in heart allografts. J. Immunol. 157 (1996) 1250-1260
27. Pannetier C., Even J., and Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol. Today. 16 (1995) 176-181
28. Gorochov G., Neumann A.U., Kereveur A., Parizot C., Li T., Katlama C., Karmochkine M., Raguin G., Autran B., and Debre P. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat. Med. 4 (1998) 215-221
29. Degauque N., Schadendorf D., Brouard S., Guillet M., Sebille F., Hohn H., Pallier A., Ruiz C., Dupont A., Chapin S., Hofmann U., Maeurer M., and Soulillou J.P. Blood T-cell Vbeta transcriptome in melanoma patients. Int. J. Cancer. 110 (2004) 721-729
30. Guille M., Andrieu M., Braudeau C., Ruiz C., Daniel N., Pallier A., Charmeteau B., Veziers J., Oden N., Bonilla N., Brouard S., Guillet J.G., and Soulillou J.P. Serial evolution of TCR beta chain transcript mobilization in HIV type-1-infected patients following vaccine immune stimulation and HAART interruption. AIDS. Res. Hum. Retroviruses. 22 (2006) 648-656
31. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14157-14162
32. Wolinsky J.S. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv. Neurol. 98 (2006) 273-292
33. Liu J., Johnson T.V., Lin J., Ramirez S.H., Bronich T.K., Caplan S., Persidsky Y., Gendelman H.E., and Kipnis J. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur. J. Immunol. 37 (2007) 3143-3154
34. Stapulionis R., Oliveira C.L., Gjelstrup M.C., Pedersen J.S., Hokland M.E., Hoffmann S.V., Poulsen K., Jacobsen C., and Vorup-Jensen T. Structural insight into the function of myelin basic protein as a ligand for integrin alpha M beta 2. J. Immunol. 180 (2008) 3946-3956
35. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., and Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
36. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., Waubant E., Gazda S., Fox R.J., Panzara M., Sarkar N., Agarwal S., and Smith C.H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 63 (2008) 395-400
37. Teitelbaum D., Aharoni R., Sela M., and Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 9528-9532
38. Khalil M., Reindl M., Lutterotti A., Kuenz B., Ehling R., Gneiss C., Lackner P., Deisenhammer F., and Berger T. Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: influence of relapses and immunomodulatory treatments. J. Neuroimmunol. 174 (2006) 147-156
39. Brenner T., Arnon R., Sela M., Abramsky O., Meiner Z., Riven-Kreitman R., Tarcik N., and Teitelbaum D. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J. Neuroimmunol. 115 (2001) 152-160
40. Farina C., Vargas V., Heydari N., Kumpfel T., Meinl E., and Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J. Neuroimmunol. 123 (2002) 188-192
41. Basile E., Gibbs E., Aziz T., and Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J. Neuroimmunol. 177 (2006) 161-166
42. Ure D.R., and Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB. J. 16 (2002) 1260-1262
43. Chofflon M., Roth S., Juillard C., Paunier A.M., Juillard P., Degroote D., and Grau G.E. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis. Eur. Cytokine. Netw. 8 (1997) 253-257
44. Calabresi P.A., Tranquill L.R., McFarland H.F., and Cowan E.P. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J. Neuroimmunol. 89 (1998) 198-205
45. Killestein J., Kalkers N.F., Meilof J.F., Barkhof F., van Lier R.A., and Polman C.H. TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS. Neurology 57 (2001) 1129-1131
46. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., and Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92 (1998) 113-121